Johnson & Johnson (JNJ)vsTG Therapeutics Inc (TGTX)
JNJ
Johnson & Johnson
$276.25
+1.43%
HEALTHCARE · Cap: $657.68B
TGTX
TG Therapeutics Inc
$59.83
+3.18%
HEALTHCARE · Cap: $8.89B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 12324% more annual revenue ($99.33B vs $799.54M). TGTX leads profitability with a 55.2% profit margin vs 16.2%. TGTX appears more attractively valued with a PEG of 1.61. TGTX earns a higher WallStSmart Score of 56/100 (C).
JNJ
Buy54
out of 100
Grade: C-
TGTX
Buy56
out of 100
Grade: C
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 25.7%
Generating 6.4B in free cash flow
Every $100 of equity generates 79 in profit
Keeps 55 of every $100 in revenue as profit
Revenue surging 70.3% year-over-year
Areas to Watch
Trading at 8.2x book value
Weak financial health signals
Expensive relative to growth rate
Premium valuation, high expectations priced in
Expensive relative to growth rate
Trading at 14.0x book value
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Operating Margin, Free Cash Flow. Profitability is solid with margins at 16.2% and operating margin at 25.7%.
Bull Case : TGTX
The strongest argument for TGTX centers on Return on Equity, Profit Margin, Revenue Growth. Profitability is solid with margins at 55.2% and operating margin at 9.0%. Revenue growth of 70.3% demonstrates continued momentum.
Bear Case : JNJ
The primary concerns for JNJ are Price/Book, Piotroski F-Score, PEG Ratio. A P/E of 41.5x leaves little room for execution misses.
Bear Case : TGTX
The primary concerns for TGTX are PEG Ratio, Price/Book, Debt/Equity.
Key Dynamics to Monitor
JNJ profiles as a mature stock while TGTX is a growth play — different risk/reward profiles.
TGTX carries more volatility with a beta of 1.80 — expect wider price swings.
TGTX is growing revenue faster at 70.3% — sustainability is the question.
JNJ generates stronger free cash flow (6.4B), providing more financial flexibility.
Bottom Line
TGTX scores higher overall (56/100 vs 54/100), backed by strong 55.2% margins and 70.3% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →TG Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
TG Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is headquartered in New York, New York.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?